Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Reserve your place

Conference Agenda

Day 1

Plenary Keynotes – Become a real-world oracle
08:30 - 09:00
Setting the scene: Drive innovation and healthcare transformation in the current political and regulatory environment

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

08:30 - 09:00
Panel: Navigating chaos? Thrive in the changing healthcare and reimbursement landscape
  • Sidestep the hurdles associated with rising healthcare costs by entering risk-sharing agreements through partnership with key stakeholders
  • Hear assessment on the potential outcomes of Obamacare and where US health insurance is headed
  • Understand the legislative and political barriers already pausing the implementation of the 21st Century Cures Act and what timelines may be resultant

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

CSL Behring Debbie Drane SVP Commercial Development CSL Behring

Stakeholder panellists TBA

08:30 - 09:00
Establish real-world value in the eyes of payers and other key stakeholders
  • What is the meaning of value and how is this interpreted by different stakeholders?
  • Harmonization is key: work together with payers to tailor value propositions to their needs
  • Envisage how Teva’s HEOR function works alongside Medical Affairs to generate robust RWE data

TEVA Riad Dirani VP, Global Health Economics and Outcomes Research Teva

08:30 - 09:00
Panel: Have clarity in your value demonstration approach with understanding of payer decision making preferences and needs
  • Plan your access strategy around the knowledge of evidence requirements from the growing myriad of assessment mechanisms
  • Define the parameters of value which can be related to specific subpopulations, personalising your value proposition
  • Optimize your use of RWE in the value equation to fill data gaps and complete the patient picture

Amgen Peter Juhn VP, Global Head of Value-based Partnerships Amgen

Novo Nordisk Stanislav Glezer Former VP Medical Affairs Novo Nordisk

FDA Nneka Onwudiwe PRO/PE Regulatory Review Officer FDA

Payer panellists TBA

08:30 - 09:00
From evidence to execution: optimize market access through internal structure
  • Equip market access functions to correctly identify and meet the differentiating needs of regional stakeholders
  • Maximize collaboration between international, country and regional market access functions to break silos, increasing internal spread of knowledge
  • Identify the roles in building robust payer value propositions and ensure continues flow of evidence creation to support commercialization post launch

EMD Serono Ana Cespedes SVP, Global Head of Market Access and Pricing EMD Serono

08:00 - 08:30
Networking Lunch Break
Section 1 - Stakeholders hold the answers
08:30 - 09:00
Move forward with confidence: The latest in FDA philosophy toward the value of RWE
  • Discover the latest updates on how the FDA approaches the use of RWE in their decision-making process
  • See how the 21st Century Cures Act is driving the use the of RWE throughout product development
  • Learn from examples of successful use of RWE to support safety and efficacy claims
  • Explore how approvals within the efficacy paradigm using RWE are stepping closer through rare diseases

FDA Jonathan Jarow Senior Medical Advisor FDA

08:30 - 09:00
Real-world payers – meet payer demands in a RWE driven environment
  • Understand how best to tailor your value demonstration based on the RWE that payers want to see
  • Reduce risk with improved real-world study design, with incorporation of payer requirements from the outset, early collaboration and partnership
  • Explore innovative new uses of big data in insurance, leading to a more preventive-care focused methodology

Company_Name Vivek Garipalli CEO Clover Health

Further speakers TBA

08:30 - 09:00
Meet evidence generation needs by making the most of the full external environment with targeted collaboration
  • See how AstraZeneca is paving the way in stakeholder partnerships to meet evidence needs through multiple case examples
  • Focus efforts based on an understanding of different external stakeholder needs
  • Overcome privacy and data challenges inhibiting the potential benefits of external collaboration

AstraZeneca Sandy Leonard VP Medical Evidence and Observational Research AstraZeneca

Section 2 - A system with data at its heart
08:30 - 09:00
The Data Journey – Make data flow safely and effectively throughout the company
  • Explore how to best make best use of a growing variety of increasingly large data sources
  • See how to ensure privacy for increasingly detailed health data with proper governance
  • Learn how to make RWD and RWE useful and engaging for different types of users

Speaker TBA

08:30 - 09:00
Empiric decision-making – the third era of evidence based medicine (EBM)
  • Utilise RWD to make near real-time decisions in the treatment process
  • Personalise treatments based on the real-world outcomes of targeted population analysis
  • An inevitable change to the practise of medicine: how do you get drugs to market in a system always basing decisions on the past?

Astellas Thomas Abbott Global Head, Real World Informatics Capabilities and Alliances Astellas

Day 2

08:30 - 09:00
Section 3.1: The next steps in the real-world data application
Section 4.1: Driving market access with a focus on value
08:30 - 09:00
Increase and accelerate RWD utilisation by colleagues throughout the organisation
  • Give your R&D colleagues the edge with linked genomic and EHR data analysis, streamlining development
  • Synthesise and communicate large data sets more quickly and efficiently with next generation analytic capabilities
  • Optimise clinical trial design with more targeted patient recruitment

Speaker TBA

Culture eats strategy for breakfast: Prioritize market access at the heart of your organisation
  • Create a culture of collaboration which aligns all departments on the ultimate goal of reimbursement
  • Establish the priorities of global market access functions and how to tailor stargates to local teams
  • Break silos: create a highly integrated cross-functional internal structure to ensure the voice of market access is represented right through the lifecycle

Speaker TBA

08:30 - 09:00
Bridge the divide between how Pharma and the FDA view RWE in regulatory decision-making
  • Build stakeholder consensus on how to define RWE in both the premarketing and post-marketing setting
  • Maximize marketplace opportunities by developing a market access strategy built around the product’s lifecycle
  • Improve value communication and promotional activities by adopting a RWE based communication strategy that is supported by a regulatory framework
  • Reduce legal and regulatory uncertainty by substantiating medical product claims and propositions on FDA led guidance

FDA Nneka Onwudiwe PRO/PE Regulatory Review Officer FDA

Maximize access with a shift towards value, not the brand
  • Distinguish your product from competitors using reliable data which backs up your value proposition
  • Fully align internal teams to communicate product value and overcome hurdles in the reimbursement process
  • Identify unmet needs of patient populations to tailor product offering, ensuring better outcomes and better access

Speaker TBA

08:30 - 09:00
Measuring comparative effectiveness in a real-world setting with pragmatic clinical trials
  • See how Sanofi's Toujeo pragmatic study is determining the efficacy and outcomes of the diabetes treatment in broad real-world populations
  • Understand how the study design allows the analysis of patient vs. physician reported outcomes accuracy
  • Explore how the study creates a more complete effectiveness picture by incorporating the wider treatment support program
  • Meet the growing range of stakeholder data requirements with a multi-layer methodological approach

Sanofi Riccardo Perfetti Senior Medical Officer, VP Global Medical Affairs, Diabetes Division Sanofi

Demonstrating value earlier in the development process
  • Hasten reimbursement by bringing products to market with a robust value proposition
  • Align internal teams to ensure evidence is generated earlier in the drug’s development for early reimbursement and successful launch
  • Establish continued collection of RWE to further address payer needs and accurately prove value to patient populations

Aetna Edmund Pezalla Former VP, National Medical Director, Pharmaceutical Policy and Strategy Aetna

08:30 - 09:00
Section 4.2: Become value centric through pricing innovations
08:30 - 09:00
Panel: The future of pragmatic trials in the United States
  • Balance your RPT approach by finding the right balance between the technical and business challenges to reduce operational risk
  • Learn how collaboration and communication throughout the build-up and operational process with the complete stakeholder ecosystem involved is key for success
  • What will the impact of the 21st Century Cures act be on the adoption of pragmatic trials

Sanofi Riccardo Perfetti Senior Medical Officer, VP Global Medical Affairs, Diabetes Division Sanofi

FDA Jonathan Jarow Senior Medical Advisor FDA

Janssen Jack Sheehan RWE Pragmatic Trial Team Lead Janssen

Value based pricing and the future of reimbursement
  • Combat concerns of rising healthcare spending by demonstrating the efficacy of your drugs and justifying the price
  • Create a simple agreement which can effectively measure effectiveness of drugs to speed up the reimbursement process
  • Monitor costs to ensure future agreements can be made, avoid spiralling costs and time constraints

Amgen Peter Juhn/span> VP, Global Head of Value-based Partnerships Amgen

08:30 - 09:00
Transform clinical trial design with RWE to accelerate development timelines
  • Explore how Flatiron Health’s collaborative project with the National Cancer Institute (NCI) is using EHR data to inform study planning
  • Identify specific patient populations and sample sizes to create a more targeted evidence generation process
  • See how the successful application of RWD will modernise the R&D paradigm

Flatiron Health Ken Carson Senior Medical Director Flatiron Health

Overcome difficulties measuring performance in value based pricing
  • Integrate patient value into the business model as a basis for sustainable industry partnership with healthcare system and payers
  • Define target patient population and simple yet conclusive outcomes measures which are agreed by relevant stakeholders
  • Build data collection systems to monitor value through measuring patient and healthcare system outcomes
  • Identify and mitigate the risk of value based agreements

Novo Nordisk Stanislav Glezer Former VP Medical Affairs Novo Nordisk

08:30 - 09:00
Section 3.2: The latest technological innovations generating and synthesizing evidence
08:30 - 09:00
Personalized and predictive medicine: Use next generation technology to find novel treatment approaches
  • See how machine learning, cognitive and deep-learning technologies are being used to find new indications in existing drugs
  • Predict undiscovered outcomes using cognitive techniques to mine through unstructured data
  • Improve identification of subpopulations to personalize treatment and better patient outcomes

Speaker TBA

Panel: From volume to value – saving the future of pharma through innovative pricing models
  • Embrace a new format of value-based pricing which guarantees reimbursement and prevents care costs spiralling out of control
  • Identify when these partnerships are most successful and how to ensure they remain mutually beneficial to pharma and provider
  • Overcome regulatory and legal barriers preventing complex pricing agreements

Speakers TBA

08:30 - 09:00
Not all data is created equal: leveraging evidence from alternative sources
  • Kickstart your data generation by effectively analyzing external prospective and retrospective data sets
  • Create robust evidence by identifying the right question while understanding the limitations of the data
  • Save time and money through analysis of virtual head-to-head RCTs
  • Take the next step – innovative ways to process and clean unstructured data and social listening

Janssen Sean McElligott Director, Global Market Access Lead Dermatology Janssen

Indication pricing - a fresh take on an old problem
  • Establish the benefits indication pricing holds for patients, payors, providers and pharma
  • Highlight the value your product delivers to specific patient subpopulations and develop a pricing strategy that reflects true effectiveness
  • Continue to gain reimbursement for innovator and specialty drugs while strengthening payor relationships by removing unnecessary spending
  • Better understand how indication pricing agreements are established and ensure you can move to a value-based pricing system in the future

ICER Bill Dreitlein Director of Pharmaceutical Policy ICER

08:30 - 09:00
Section 4.3: It's never too early for evidence: preparing for partnerships and launch success
08:30 - 09:00
Panel: Overcome data quality issues to successfully meet evidence needs through the latest digital health technologies
  • Leverage the latest analytical innovations to turn raw prospective data into valued insight, discovering previously unmet needs
  • See how real-time collection of data will move healthcare further into the preventive landscape
  • More than just a novel idea: Explore examples of the latest tools being developed and implanted to overcome data standards issues creating true RWD

UnitedHealthcare Vidya Raman-Tangella SVP, Head Innovation Center of Excellence UnitedHealthcare

UCB Andy Gunn Global Head of Evidence Generation Strategy UCB

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

From medical to marketing - Increase product launch success with increased visualization of the drug lifecycle
  • Use real word insights to better understand patient populations and indications and tailor value propositions
  • See how market access teams can be the bridge between pre-launch strategy and post-launch commercial teams
  • Identify new areas of the drug lifecycle to generate evidence and ensure learnings are transferred across the entire portfolio

Speaker TBA

08:30 - 09:00
The future of data ownership: Overcome data sharing, privacy and security concerns simultaneously with blockchain technology
  • Enhance patient data security with greater encryption and a “shared risk economy” with removal of centralized data hubs
  • Create a fuller picture of the patient with a standardized EHR system
  • Move toward a more patient centric system by giving patients ownership of their own personal data

Speaker TBA

Panel: Proving Real-World value to payors
  • Meet the RWE requirements of key payors by establishing a dialog earlier in the drug development process
  • Further understand what payors are looking for and how to demonstrate value using evidence generated from real world sources
  • Identify the difference in requirements of a range of different payors and establish methods for contained collaboration to benefit future agreements

Institute for Clinical & Economic Review Foluso Agboola Research Scientist, Comparative Effectiveness Lead Institute for Clinical & Economic Review

Further Industry Speakers TBA

Day 1

Plenary Keynotes – Become a real-world oracle
08:30 - 09:00
Setting the scene: Drive innovation and healthcare transformation in the current political and regulatory environment

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

08:30 - 09:00
Panel: Navigating chaos? Thrive in the changing healthcare and reimbursement landscape
  • Sidestep the hurdles associated with rising healthcare costs by entering risk-sharing agreements through partnership with key stakeholders
  • Hear assessment on the potential outcomes of Obamacare and where US health insurance is headed
  • Understand the legislative and political barriers already pausing the implementation of the 21st Century Cures Act and what timelines may be resultant

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

CSL Behring Debbie Drane SVP Commercial Development CSL Behring

Stakeholder panellists TBA

08:30 - 09:00
Establish real-world value in the eyes of payers and other key stakeholders
  • What is the meaning of value and how is this interpreted by different stakeholders?
  • Harmonization is key: work together with payers to tailor value propositions to their needs
  • Envisage how Teva’s HEOR function works alongside Medical Affairs to generate robust RWE data

TEVA Riad Dirani VP, Global Health Economics and Outcomes Research Teva

08:30 - 09:00
Panel: Have clarity in your value demonstration approach with understanding of payer decision making preferences and needs
  • Plan your access strategy around the knowledge of evidence requirements from the growing myriad of assessment mechanisms
  • Define the parameters of value which can be related to specific subpopulations, personalising your value proposition
  • Optimize your use of RWE in the value equation to fill data gaps and complete the patient picture

Amgen Peter Juhn VP, Global Head of Value-based Partnerships Amgen

Novo Nordisk Stanislav Glezer Former VP Medical Affairs Novo Nordisk

FDA Nneka Onwudiwe PRO/PE Regulatory Review Officer FDA

Payer panellists TBA

08:30 - 09:00
From evidence to execution: optimize market access through internal structure
  • Equip market access functions to correctly identify and meet the differentiating needs of regional stakeholders
  • Maximize collaboration between international, country and regional market access functions to break silos, increasing internal spread of knowledge
  • Identify the roles in building robust payer value propositions and ensure continues flow of evidence creation to support commercialization post launch

EMD Serono Ana Cespedes SVP, Global Head of Market Access and Pricing EMD Serono

08:00 - 08:30
Networking Lunch Break
Section 1 - Stakeholders hold the answers
08:30 - 09:00
Move forward with confidence: The latest in FDA philosophy toward the value of RWE
  • Discover the latest updates on how the FDA approaches the use of RWE in their decision-making process
  • See how the 21st Century Cures Act is driving the use the of RWE throughout product development
  • Learn from examples of successful use of RWE to support safety and efficacy claims
  • Explore how approvals within the efficacy paradigm using RWE are stepping closer through rare diseases

FDA Jonathan Jarow Senior Medical Advisor FDA

08:30 - 09:00
Real-world payers – meet payer demands in a RWE driven environment
  • Understand how best to tailor your value demonstration based on the RWE that payers want to see
  • Reduce risk with improved real-world study design, with incorporation of payer requirements from the outset, early collaboration and partnership
  • Explore innovative new uses of big data in insurance, leading to a more preventive-care focused methodology

Company_Name Vivek Garipalli CEO Clover Health

Further speakers TBA

08:30 - 09:00
Meet evidence generation needs by making the most of the full external environment with targeted collaboration
  • See how AstraZeneca is paving the way in stakeholder partnerships to meet evidence needs through multiple case examples
  • Focus efforts based on an understanding of different external stakeholder needs
  • Overcome privacy and data challenges inhibiting the potential benefits of external collaboration

AstraZeneca Sandy Leonard VP Medical Evidence and Observational Research AstraZeneca

Section 2 - A system with data at its heart
08:30 - 09:00
The Data Journey – Make data flow safely and effectively throughout the company
  • Explore how to best make best use of a growing variety of increasingly large data sources
  • See how to ensure privacy for increasingly detailed health data with proper governance
  • Learn how to make RWD and RWE useful and engaging for different types of users

Speaker TBA

08:30 - 09:00
Empiric decision-making – the third era of evidence based medicine (EBM)
  • Utilise RWD to make near real-time decisions in the treatment process
  • Personalise treatments based on the real-world outcomes of targeted population analysis
  • An inevitable change to the practise of medicine: how do you get drugs to market in a system always basing decisions on the past?

Astellas Thomas Abbott Global Head, Real World Informatics Capabilities and Alliances Astellas

Download your event brochure today

Full speaker list • Full conference agenda • Audience breakdown

Day 2

08:30 - 09:00
Section 3.1: The next steps in the real-world data application
Section 4.1: Driving market access with a focus on value
08:30 - 09:00
Increase and accelerate RWD utilisation by colleagues throughout the organisation
  • Give your R&D colleagues the edge with linked genomic and EHR data analysis, streamlining development
  • Synthesise and communicate large data sets more quickly and efficiently with next generation analytic capabilities
  • Optimise clinical trial design with more targeted patient recruitment

Speaker TBA

Culture eats strategy for breakfast: Prioritize market access at the heart of your organisation
  • Create a culture of collaboration which aligns all departments on the ultimate goal of reimbursement
  • Establish the priorities of global market access functions and how to tailor stargates to local teams
  • Break silos: create a highly integrated cross-functional internal structure to ensure the voice of market access is represented right through the lifecycle

Speaker TBA

08:30 - 09:00
Bridge the divide between how Pharma and the FDA view RWE in regulatory decision-making
  • Build stakeholder consensus on how to define RWE in both the premarketing and post-marketing setting
  • Maximize marketplace opportunities by developing a market access strategy built around the product’s lifecycle
  • Improve value communication and promotional activities by adopting a RWE based communication strategy that is supported by a regulatory framework
  • Reduce legal and regulatory uncertainty by substantiating medical product claims and propositions on FDA led guidance

FDA Nneka Onwudiwe PRO/PE Regulatory Review Officer FDA

Maximize access with a shift towards value, not the brand
  • Distinguish your product from competitors using reliable data which backs up your value proposition
  • Fully align internal teams to communicate product value and overcome hurdles in the reimbursement process
  • Identify unmet needs of patient populations to tailor product offering, ensuring better outcomes and better access

Speaker TBA

08:30 - 09:00
Measuring comparative effectiveness in a real-world setting with pragmatic clinical trials
  • See how Sanofi's Toujeo pragmatic study is determining the efficacy and outcomes of the diabetes treatment in broad real-world populations
  • Understand how the study design allows the analysis of patient vs. physician reported outcomes accuracy
  • Explore how the study creates a more complete effectiveness picture by incorporating the wider treatment support program
  • Meet the growing range of stakeholder data requirements with a multi-layer methodological approach

Sanofi Riccardo Perfetti Senior Medical Officer, VP Global Medical Affairs, Diabetes Division Sanofi

Demonstrating value earlier in the development process
  • Hasten reimbursement by bringing products to market with a robust value proposition
  • Align internal teams to ensure evidence is generated earlier in the drug’s development for early reimbursement and successful launch
  • Establish continued collection of RWE to further address payer needs and accurately prove value to patient populations

Aetna Edmund Pezalla Former VP, National Medical Director, Pharmaceutical Policy and Strategy Aetna

08:30 - 09:00
Section 4.2: Become value centric through pricing innovations
08:30 - 09:00
Panel: The future of pragmatic trials in the United States
  • Balance your RPT approach by finding the right balance between the technical and business challenges to reduce operational risk
  • Learn how collaboration and communication throughout the build-up and operational process with the complete stakeholder ecosystem involved is key for success
  • What will the impact of the 21st Century Cures act be on the adoption of pragmatic trials

Sanofi Riccardo Perfetti Senior Medical Officer, VP Global Medical Affairs, Diabetes Division Sanofi

FDA Jonathan Jarow Senior Medical Advisor FDA

Janssen Jack Sheehan RWE Pragmatic Trial Team Lead Janssen

Value based pricing and the future of reimbursement
  • Combat concerns of rising healthcare spending by demonstrating the efficacy of your drugs and justifying the price
  • Create a simple agreement which can effectively measure effectiveness of drugs to speed up the reimbursement process
  • Monitor costs to ensure future agreements can be made, avoid spiralling costs and time constraints

Amgen Peter Juhn/span> VP, Global Head of Value-based Partnerships Amgen

08:30 - 09:00
Transform clinical trial design with RWE to accelerate development timelines
  • Explore how Flatiron Health’s collaborative project with the National Cancer Institute (NCI) is using EHR data to inform study planning
  • Identify specific patient populations and sample sizes to create a more targeted evidence generation process
  • See how the successful application of RWD will modernise the R&D paradigm

Flatiron Health Ken Carson Senior Medical Director Flatiron Health

Overcome difficulties measuring performance in value based pricing
  • Integrate patient value into the business model as a basis for sustainable industry partnership with healthcare system and payers
  • Define target patient population and simple yet conclusive outcomes measures which are agreed by relevant stakeholders
  • Build data collection systems to monitor value through measuring patient and healthcare system outcomes
  • Identify and mitigate the risk of value based agreements

Novo Nordisk Stanislav Glezer Former VP Medical Affairs Novo Nordisk

08:30 - 09:00
Section 3.2: The latest technological innovations generating and synthesizing evidence
08:30 - 09:00
Personalized and predictive medicine: Use next generation technology to find novel treatment approaches
  • See how machine learning, cognitive and deep-learning technologies are being used to find new indications in existing drugs
  • Predict undiscovered outcomes using cognitive techniques to mine through unstructured data
  • Improve identification of subpopulations to personalize treatment and better patient outcomes

Speaker TBA

Panel: From volume to value – saving the future of pharma through innovative pricing models
  • Embrace a new format of value-based pricing which guarantees reimbursement and prevents care costs spiralling out of control
  • Identify when these partnerships are most successful and how to ensure they remain mutually beneficial to pharma and provider
  • Overcome regulatory and legal barriers preventing complex pricing agreements

Speakers TBA

08:30 - 09:00
Not all data is created equal: leveraging evidence from alternative sources
  • Kickstart your data generation by effectively analyzing external prospective and retrospective data sets
  • Create robust evidence by identifying the right question while understanding the limitations of the data
  • Save time and money through analysis of virtual head-to-head RCTs
  • Take the next step – innovative ways to process and clean unstructured data and social listening

Janssen Sean McElligott Director, Global Market Access Lead Dermatology Janssen

Indication pricing - a fresh take on an old problem
  • Establish the benefits indication pricing holds for patients, payors, providers and pharma
  • Highlight the value your product delivers to specific patient subpopulations and develop a pricing strategy that reflects true effectiveness
  • Continue to gain reimbursement for innovator and specialty drugs while strengthening payor relationships by removing unnecessary spending
  • Better understand how indication pricing agreements are established and ensure you can move to a value-based pricing system in the future

ICER Bill Dreitlein Director of Pharmaceutical Policy ICER

08:30 - 09:00
Section 4.3: It's never too early for evidence: preparing for partnerships and launch success
08:30 - 09:00
Panel: Overcome data quality issues to successfully meet evidence needs through the latest digital health technologies
  • Leverage the latest analytical innovations to turn raw prospective data into valued insight, discovering previously unmet needs
  • See how real-time collection of data will move healthcare further into the preventive landscape
  • More than just a novel idea: Explore examples of the latest tools being developed and implanted to overcome data standards issues creating true RWD

UnitedHealthcare Vidya Raman-Tangella SVP, Head Innovation Center of Excellence UnitedHealthcare

UCB Andy Gunn Global Head of Evidence Generation Strategy UCB

Otsuka John Bardi VP Government Affairs, Advocacy & Digital Medicines Business Development Otsuka

From medical to marketing - Increase product launch success with increased visualization of the drug lifecycle
  • Use real word insights to better understand patient populations and indications and tailor value propositions
  • See how market access teams can be the bridge between pre-launch strategy and post-launch commercial teams
  • Identify new areas of the drug lifecycle to generate evidence and ensure learnings are transferred across the entire portfolio

Speaker TBA

08:30 - 09:00
The future of data ownership: Overcome data sharing, privacy and security concerns simultaneously with blockchain technology
  • Enhance patient data security with greater encryption and a “shared risk economy” with removal of centralized data hubs
  • Create a fuller picture of the patient with a standardized EHR system
  • Move toward a more patient centric system by giving patients ownership of their own personal data

Speaker TBA

Panel: Proving Real-World value to payors
  • Meet the RWE requirements of key payors by establishing a dialog earlier in the drug development process
  • Further understand what payors are looking for and how to demonstrate value using evidence generated from real world sources
  • Identify the difference in requirements of a range of different payors and establish methods for contained collaboration to benefit future agreements

Institute for Clinical & Economic Review Foluso Agboola Research Scientist, Comparative Effectiveness Lead Institute for Clinical & Economic Review

Further Industry Speakers TBA

Download your event brochure today

Complete speaker line-up • Program for all tracks & sessions • Audience breakdown